Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: Correlation with interstitial lung disease

Rheumatology

Volumn 41, Issue 11, 2002, Pages 1268-1272

  Ihn, H ^a   Asano, Y ^a   Kubo, M ^a   Yamane, K ^a   Jinnin, M ^a   Yazawa, N ^a   Fujimoto, M ^a   Tamaki, K ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Enzyme linked immunosorbent assay; Interstitial lung disease; Vital capacity

Indexed keywords

BIOLOGICAL MARKER; SURFACTANT PROTEIN D;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DERMATOMYOSITIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN BIOPSY; VITAL CAPACITY;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DERMATOMYOSITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; POLYMYOSITIS; PROBABILITY; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; REFERENCE VALUES; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 0036851420     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Arsura EL, Greenberg AS. Adverse impact of interstitial pulmonary fibrosis on progression in polymyositis and dermatomyositis. Semin Arthritis Rheum 1988;19:153-60.
2. Hidano A, Torikai S, Uemura T, Shimizu S. Malignancy and interstitial pneumonitis as fatal complication in dermatomyositis. J Dermatol 1992;19:153-60.
3. Persson A, Rust K, Chang D, Moxley M, Longmore W, Crouch E. CP4: a pneumocyte-derived collagenous surfactant-associated protein-evidence for heterogeneity of collagenous surfactant proteins. Biochemistry 1988; 27:8576-84.
4. van Iwaarden F, Welmers B, Verhoef J, Haagsman HP, van Golde LMG. Pulmonary surfactant protein A enhances the host-defence mechanism of rat alveolar macrophages. Am J Respir Cell Mol Biol 1990;2:91-8.
5. Nagae H, Takahashi H, Kuroki Y et al. Enzyme-linked immunosorbent assay using F(ab)′2 fragment for the detection of pulmonary surfactant protein D in sera. Clin Chim Acta 1997;266:157-71.
6. Honda Y, Kuroki Y, Matsuura E et al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995;152:1860-6.
7. Kuroki Y, Takahashi H, Chiba H, Akino T. Surfactant proteins A and D: disease markers. Biochim Biophys Acta 1998;1408:334-45.
8. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-7.
9. Asano Y, Ihn H, Yamane K et al. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. Arthritis Rheum 2001;44:1363-9.
10. Ihn H, Sato S, Tamaki T, Soma Y et al. Clinical evaluation of scleroderma spectrum disorders using a points system. Arch Dermatol Res 1992;284:391-5.
11. Yamane K, Ihn H, Kubo M et al. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J Rheumatol 2000; 27:930-4.
12. Dulkerian SJ, Gonzales LW, Ning Y, Ballard PL. Regulation of surfactant protein D in human fetal lung. Am J Respir Cell Mol Biol 1996;15:781-6.
13. Kubo M, Ihn H, Yamane K et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology 2000;39:632-6.